Miv Therapeutics (India) Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 07-05-2024
- Paid Up Capital ₹ 8.22 Cr
as on 07-05-2024
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 15.86 Cr
as on 07-05-2024
- Revenue 10.03%
(FY 2019)
- Profit -42.95%
(FY 2019)
- Ebitda 8.50%
(FY 2019)
- Net Worth 3.22%
(FY 2019)
- Total Assets 24.27%
(FY 2019)
About Miv Therapeutics (India)
- CIN/LLPIN
U33112GJ2006PTC048811
- Company No.
048811
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2006
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Miv Therapeutics (India) Private Limited offer?
Miv Therapeutics (India) Private Limited offers a wide range of products and services, including Endoscopy & Laparoscopy instruments, Surgical Equipments.
Who are the key members and board of directors at Miv Therapeutics (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhavi Jawale  | Company Secretary | 02-Jul-2018 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mathew Thomas | Director | 24-Aug-2011 | Current |
| Brian Lancelot | Director | 24-Aug-2011 | Current |
| Rajesh Shrivas | Director | 24-Aug-2011 | Current |
| Murlidhar Bendale | Director | 22-May-2012 | Current |
Financial Performance of Miv Therapeutics (India).
Miv Therapeutics (India) Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 10.03% increase. The company also saw a substantial fall in profitability, with a 42.95% decrease in profit. The company's net worth moved up by a moderate rise of 3.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Miv Therapeutics (India)?
In 2019, Miv Therapeutics (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Purple Microport Cardiovascular Private LimitedActive 17 years 3 months
Brian Lancelot and Rajesh Shrivas are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Shamrao Vithal Co-Operative Bank Limited Creation Date: 02 Jan 2013 | ₹2.00 Cr | Satisfied |
The Shamrao Vithal Co-Operative Bank Limited Creation Date: 02 Jan 2013 | ₹9.00 M | Satisfied |
Central Bank Of India Creation Date: 01 Dec 2006 | ₹5.06 Cr | Satisfied |
How Many Employees Work at Miv Therapeutics (India)?
Unlock and access historical data on people associated with Miv Therapeutics (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Miv Therapeutics (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Miv Therapeutics (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
